Official reprint from UpToDate®

www.uptodate.com © 2024 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Obesity in adults: Overview of management

AUTHORS: Leigh Perreault, MD, Caroline Apovian, MD
SECTION EDITORS: F Xavier Pi-Sunyer, MD, MPH, David Seres, MD
DEPUTY EDITOR: Sara Swenson, MD

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Mar 2024.

This topic last updated: Mar 07, 2024.

INTRODUCTION

The morbidity and mortality associated with having overweight or obesity have been known to the medical
profession since the time of Hippocrates more than 2500 years ago. Overweight refers to a weight above the
"normal" range, with normal defined on the basis of actuarial data. This is determined by calculating the body
mass index (BMI, defined as the weight in kilograms divided by height in meters squared). Overweight is
defined as a BMI of 25 to 29.9 kg/m2; obesity is defined as a BMI of ≥30 kg/m2. Severe obesity is defined as a
BMI ≥40 kg/m2 (or ≥35 kg/m2 in the presence of comorbidities) (calculator 1). Although these categorical
definitions are clinically useful, it is clear that the risks imparted by increasing body mass follow a continuum
and vary considerably between individuals.

An overview of the management of obesity is provided here. Information on screening, evaluation, health
hazards associated with obesity, and specific therapies are reviewed in detail elsewhere.

● (See "Obesity in adults: Prevalence, screening, and evaluation".)

● (See "Overweight and obesity in adults: Health consequences".)

● (See "Obesity in adults: Dietary therapy".)

● (See "Obesity in adults: Role of physical activity and exercise".)

● (See "Obesity in adults: Behavioral therapy".)

● (See "Obesity in adults: Drug therapy".)

● (See "Bariatric procedures for the management of severe obesity: Descriptions".)

● (See "Bariatric surgery for management of obesity: Indications and preoperative preparation".)

● (See "Outcomes of bariatric surgery".)

● (See "Intragastric balloon therapy for weight loss".)

IMPORTANCE OF WEIGHT LOSS

The medical rationale for weight loss in people with obesity is that obesity is a disease associated with a
significant increase in mortality ( figure 1) and many health risks, including type 2 diabetes mellitus,
hypertension, dyslipidemia, and coronary heart disease. The higher the body mass index (BMI), the greater the
risk of morbidity and mortality [1]. The relationship between BMI and mortality is likely to be similar for all races
and ethnicities, but the minimal BMI where excess risk is seen may differ. These risks are reviewed in detail
separately. (See "Overweight and obesity in adults: Health consequences".)

Morbidity — Life insurance reports, the first to suggest that lower body weight was associated with lower
morbidity and mortality, have been corroborated by the Behavioral Risk Factor Surveillance System (BRFSS)
among other studies [2]. Furthermore, randomized trials inducing weight loss via lifestyle, pharmacologic
therapy, or bariatric surgical procedures have been shown to reduce a wide array of weight-related morbidity
[1,3-5].

As an example, in the frequently cited Diabetes Prevention Program (DPP), intensive lifestyle modification
focusing on weight loss reduced the rate of progression from impaired glucose tolerance to diabetes over three
years [6]. The efficacy of the intensive lifestyle modification persisted over 15 years but was somewhat
attenuated over time. There was also a persistent reduction in risk factors for cardiovascular disease (CVD) [7,8],
although no reduction was observed for all-cause, cancer-related, or cardiovascular mortality at 21 years of
follow-up [9]. In similar trials evaluating intensive clinician-supervised weight loss, remission of type 2 diabetes
was reported in approximately 50 percent of patients [10,11].

Other trials have also reported a beneficial effect of weight loss on additional CVD risk factors, including blood
pressure [12,13] and plasma lipid levels [14], as well as a reduction in cardiovascular events [15], although the
latter was only seen after bariatric surgery. Additional benefits of weight loss include improvements in urinary
incontinence, sleep apnea, depression, quality of life, physical functioning, and mobility. (See "Obesity:
Association with cardiovascular disease", section on 'Benefits of weight loss' and "Overweight, obesity, and
weight reduction in hypertension", section on 'Long-term effects of weight reduction' and "Overweight and
obesity in adults: Health consequences", section on 'Morbidity'.)

Mortality — Evidence from observational studies and randomized trials suggest that weight loss (including
nonsurgical and surgical weight loss approaches) in people with overweight and obesity is associated with a
reduction in overall mortality [13,16-20]. (See "Outcomes of bariatric surgery".)

In the Look AHEAD (Action for Health in Diabetes) trial, 5145 individuals with type 2 diabetes and BMI >25 kg/m2
were randomly assigned to an intensive lifestyle intervention (group and individual meetings to achieve weight
loss with diet and exercise) or standard diabetes education [21]. After a median follow-up of 9.6 years, the
composite primary outcome (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke,
and hospitalization for angina) occurred in a similar number of patients in the intervention and control groups
[22]. Possible reasons for this finding include the lower-than-expected rates of cardiovascular events in both
groups, improved overall cardiovascular risk factor treatment with medical therapy (eg, antihypertensives,
statins), enrollment of a relatively healthy patient population, and gradual weight loss in the control group such
that the differential weight loss between the two groups was only 2.5 percent at study end [23]. However,
among those trial participants who lost >10 percent of their weight over the first year, there was a 20 percent
risk reduction in the primary composite outcome [3]. Furthermore, the intervention group achieved its results
with less use of CVD risk-lowering medications than the control group.

APPROACH TO THERAPY
The approach to management outlined below is based upon available clinical trial evidence (reviewed in the
individual topics), clinical expertise, and patient preference, and is largely in agreement with published
guidelines [24].

Goals of treatment — The goal of therapy is to prevent, treat, or reverse the complications of obesity and
improve quality of life [24,25]. Health benefits have been reported with weight loss of as little as 5 percent of
body weight [6]. Many patients, however, have a weight loss goal of 30 percent or more below their current
weight, a goal that is often not achievable without bariatric surgery. With lifestyle measures alone, a weight loss
of 5 to 7 percent of body weight is more typical but often difficult to maintain. In trials comparing
pharmacologic therapy with placebo, weight loss of 5 to 10 percent using both drug and behavioral intervention
is considered a very good response, and weight loss exceeding 10 percent is considered an excellent response.
Hence, it is helpful to understand the expected magnitude of weight loss with any given intervention in order to
align it with the patient's goal. Of note, in a randomized trial, treatment with semaglutide resulted in an 14.9
percent average weight loss, with roughly one-third of patients achieving ≥20 percent weight loss at one year
[26]. These results suggest that developments in pharmacotherapies may ultimately yield weight loss results
approaching those seen in bariatric surgery.

Identify candidates — Assessment of an individual's overall risk status includes determination of the degree of
overweight (body mass index [BMI]), the presence of abdominal obesity (waist circumference), and the presence
of cardiovascular disease (CVD) risk factors (eg, hypertension, diabetes, dyslipidemia) or other comorbidities (eg,
sleep apnea, nonalcoholic fatty liver disease). The relationship between BMI and risk for weight-related health
complications allows identification of patients appropriate for weight loss intervention. (See "Obesity in adults:
Prevalence, screening, and evaluation", section on 'Assessing obesity-related health risk'.)

● Little or no risk – A BMI of 20 to 25 kg/m2 is associated with little or no increased risk unless waist
circumference is high (a marker of increased cardiometabolic risk) or the person has gained more than 10
kg since age 18 years. Asian individuals start to incur risk, even in this low range (ie, BMI >23 kg/m2). (See
"Obesity in adults: Prevalence, screening, and evaluation", section on 'BMI-based classifications'.)

● Low risk – Individuals with a BMI of 25 to 29.9 kg/m2, who do not have risk factors for CVD or other
weight-related comorbidities, may be described as having low risk, particularly if they are older. They
should receive counseling on prevention of weight gain, including advice on dietary habits and physical
activity. (See "Obesity in adults: Behavioral therapy".)

● Moderate risk – Individuals with a BMI between 25 and 29.9 kg/m2 and with one or more risk factors for
CVD (diabetes, hypertension, dyslipidemia), or with a BMI of 30 to 34.9 kg/m2, are at moderate risk. Such
patients should be offered or referred to intensive, multicomponent behavioral intervention [27]. This
includes tools and strategies to make dietary changes, increase physical activity, and support and maintain
weight loss. Pharmacologic therapy should also be considered.

● High risk – Individuals with a BMI of 35 to 40 kg/m2 are at high risk, especially those ages 20 to 39 [28], as
well as those with a BMI above 40 kg/m2. Individuals in the highest-risk categories should receive the most
aggressive treatment (intensive, multicomponent behavioral intervention, pharmacologic therapy, bariatric
surgery). (See "Obesity in adults: Behavioral therapy" and "Obesity in adults: Drug therapy" and "Bariatric
surgery for management of obesity: Indications and preoperative preparation".)

BMI is calculated as follows:

BMI = Body weight (in kg) ÷ height squared, in meters (calculator 1)

BMI is correlated with body fat. Overweight and obesity are defined as a BMI between 25 and 29.9 kg/m2 and a
BMI ≥30 kg/m2, respectively. As noted, an elevated BMI is a necessary basis for treatment. (See "Obesity in
adults: Prevalence, screening, and evaluation", section on 'Body mass index'.)

Waist circumference is measured with a metal or plastic, nondistensible tape measure, placed around the
abdomen parallel to the floor at the level of the iliac crest with the patient standing ( figure 2). A waist
circumference of ≥40 inches (102 cm) for men and ≥35 inches (88 cm) for women is considered elevated and
indicative of increased cardiometabolic risk [1]. In the BMI range of 25 to 35 kg/m2, an increased waist
circumference may indicate need for more aggressive treatment [1]. (See "Obesity in adults: Prevalence,
screening, and evaluation", section on 'Waist circumference'.)

However, there is ethnic variability in waist circumference values that predict increased risk. As an example,
Japanese Americans and Indians from South Asia have more total fat and visceral fat and therefore may be at
higher risk of developing type 2 diabetes for a given BMI than White persons. In Asian females, waist
circumference >80 cm (31.5 inches) and in Asian males a value >90 cm (35.4 inches) are considered abnormal.
(See "Obesity in adults: Prevalence, screening, and evaluation", section on 'Waist circumference'.)

Initial treatment — The initial management of individuals who would benefit from weight loss is a
comprehensive lifestyle intervention: a combination of diet, exercise, and behavioral modification. All patients
who would benefit from weight loss should receive counseling on diet, exercise, and goals for weight loss. The
behavioral modification component facilitates adherence to diet and exercise regimens, and includes regular
self-monitoring of food intake, physical activity, and weight. The role of behavioral therapy, diet, and exercise in
the treatment of obesity are reviewed in detail separately. (See "Obesity in adults: Behavioral therapy" and
"Obesity in adults: Dietary therapy", section on 'Goals of weight loss' and "Obesity in adults: Role of physical
activity and exercise".)

Comprehensive lifestyle intervention — One example of a successful comprehensive lifestyle intervention

program is the Diabetes Prevention Program (DPP) [6], subsequently used in the Look AHEAD (Action for Health
in Diabetes) study [22]. The two major goals of the DPP lifestyle intervention were a minimum of 7 percent
weight loss through a low-fat, hypocaloric diet and a minimum of 150 minutes of exercise per week (such as
brisk walking). Several behavioral components were used to help achieve these goals, including behavioral self-
management training, individual case managers, group and/or individual sessions, individualized adherence
strategies, and a network of training, feedback, and clinical support [29]. Using this approach, lifestyle
intervention was more effective for preventing diabetes than a pharmacologic intervention (metformin); 58
versus 31 percent risk reduction at 3.1 years [6]. (See "Prevention of type 2 diabetes mellitus" and "Obesity in
adults: Role of physical activity and exercise" and "Obesity in adults: Dietary therapy".)

Although a number of commercially available weight loss programs boast >10 percent weight loss, a meta-
analysis of 22 behavioral weight loss studies showed just over 4 percent average loss compared with 1 percent
for the control groups, with maximal effect within the first six months after the initiation of treatment [6,30,31].
Regrettably, as with other therapies for obesity, maintenance of these initial weight losses has been difficult
[32].

Dietary therapy — Many types of diets produce modest weight loss. Options include balanced low-calorie,
low-fat/low-calorie, moderate-fat/low-calorie, or low-carbohydrate diets, as well as the Mediterranean diet. Diets
can be consumed conventionally or on a time-restricted basis (ie, intermittent fasting). Dietary adherence is an
important predictor of weight loss, regardless of the type of diet chosen [33]. Thus, we advise tailoring a diet
that reduces energy intake below energy expenditure to individual patient preferences, rather than focusing on
the macronutrient composition of the diet. The addition of dietary counseling may facilitate weight loss,
particularly during the first year. (See "Obesity in adults: Dietary therapy", section on 'Types of diets'.)

Metabolic studies using state-of-the-art techniques have concluded that most adults will lose weight when fed
<1000 kcal/day. Thus, even subjects who are concerned that they are "metabolically resistant" to weight loss will
lose weight if they comply with a diet of 800 to 1200 kcal/day. More severe caloric restriction might be expected
to induce weight loss more quickly, but a comparison with 400 versus 800 kcal/day diet formulas showed no
difference in weight loss [34], presumably due to slowing of resting metabolic rate. We thus advise diets
consisting of >800 kcal/day. (See "Obesity in adults: Dietary therapy", section on 'Very low-calorie diets'.)

In addition, because of the body's hormonal adaptation to perceived starvation, it is difficult to maintain a very
low-calorie diet long term. However, these diets may be used in certain conditions when rapid weight loss is
needed (eg, to obtain metabolic control in uncontrolled type 2 diabetes mellitus or hypertension, or in
preparation for a surgical procedure such as joint replacement, bariatric surgery, or organ transplantation).

Other dietary patterns, such as intermittent fasting (eg, alternate-day fasting or time-restricted feeding) are
sometimes used to promote weight loss, although the evidence of their efficacy is mixed. (See "Obesity in
adults: Dietary therapy", section on 'Intermittent fasting'.)

No matter which diet or dietary pattern is chosen, continued surveillance by both clinician and patient are
essential for treatment success. Return visits with the clinician, dietician, or behaviorist should be scheduled at
regular intervals to assess barriers, discuss next steps, and offer encouragement. If weight loss is less than 5
percent in the first six months, something else should be tried. (See "Obesity in adults: Behavioral therapy" and
"Obesity in adults: Dietary therapy".)

Exercise — Although less potent than dietary restriction in promoting weight loss, increasing energy
expenditure through physical activity is a strong predictor of weight loss maintenance. In addition, physical
activity can attenuate the loss of lean mass (eg, muscle) during active weight loss [35]. Physical activity should
be performed for approximately 30 minutes or more, five to seven days a week, to prevent weight gain and to
improve cardiovascular health [36]. There appears to be a dose effect for physical activity and weight loss, and
much greater amounts of exercise are necessary to produce significant weight loss in the absence of a
calorically restricted diet. Therefore, when weight loss is the desired goal, a calorie-restricted diet should be
combined with less sedentary time and increased physical activity; the activity should be gradually increased
over time as tolerated. A multicomponent program that includes aerobic and resistance training is preferred.
Existing medical conditions, age, and preferences for types of exercise should all be considered in the decisions.
(See "Obesity in adults: Role of physical activity and exercise" and "Exercise prescription and guidance for
adults", section on 'Prescribing an exercise program'.)

Behavior modification — Behavior modification or behavior therapy is one cornerstone in the treatment for
obesity. The goal of behavioral therapy is to help patients make long-term changes in their eating behavior by
modifying and monitoring their food intake, modifying their physical activity, and controlling cues and stimuli in
the environment that trigger eating. These concepts are usually included in programs conducted by
psychologists or other trained personnel as well as many self-help groups. (See "Obesity in adults: Behavioral
therapy".)

Subsequent treatment — For patients who are unable to achieve weight loss goals with a comprehensive
lifestyle intervention alone, options include pharmacologic therapy, the use of medical devices, or bariatric
surgery. (See "Obesity in adults: Drug therapy" and "Bariatric surgery for management of obesity: Indications
and preoperative preparation".)
 Drug therapy — Drug therapy is often a helpful component in the treatment regimen for people with obesity;
it can be considered for those with a BMI >30 kg/m2, or a BMI of 27 to 29.9 kg/m2 with weight-related
comorbidities, who have not met weight loss goals (loss of at least 5 percent of total body weight at three to six
months) with a comprehensive lifestyle intervention. The decision to initiate drug therapy should be
individualized and made after a careful evaluation of the risks and benefits of all treatment options. (See
"Obesity in adults: Drug therapy", section on 'Our approach'.)

The choice of antiobesity drug depends upon medication efficacy and adverse effects, patient comorbidities and
preferences, and insurance coverage and out-of-pocket costs. For most patients, an incretin-based medication
(eg, tirzepatide, semaglutide) is the preferred first-line pharmacotherapy. Other options include alternative
glucagon-like peptide 1 (GLP-1) receptor agonists (eg, liraglutide), phentermine-topiramate, naltrexone-
bupropion, orlistat, and phentermine (as a single agent). The details of pharmacotherapy for the management
of obesity are reviewed elsewhere. (See "Obesity in adults: Drug therapy".)

Devices — There are several types of devices approved for use in the treatment of obesity. The use of one of
these devices may be considered for use in those patients in whom medications are ineffective or not tolerated,
for those patients who are unable or unwilling to undergo bariatric surgery, or as a bridging therapy prior to
bariatric surgery. (See "Intragastric balloon therapy for weight loss", section on 'Indications'.)

In referring a patient to receive one of these devices, it is important to note that the BMI indication for each
device is different, with a BMI range between 25 to 55 kg/m2. In addition, the majority of insurance companies
in the United States do not cover the costs of these devices; the financial burden to the patient may be
significant depending upon which device is used. In addition to cost, recommendations for the use of any of
these devices is dependent upon many other factors, including patient comorbidities, preferences, and weight
loss goals.

● Intragastric balloon systems – With these techniques, saline filled balloons are placed in the stomach to
take up space and produce a sensation of satiety ( figure 3). They are indicated for weight reduction in
conjunction with diet and exercise in adult patients with a BMI of 30 to 40 kg/m2 and one or more obesity-
related comorbid conditions, or for adult patients with obesity who have failed weight reduction with diet
and exercise alone. There are five intragastric balloon systems available, three of which are approved by
the United States (US) Food and Drug Administration (FDA). Of the three balloon systems available for use
in the US, two of these devices are placed endoscopically while the other is swallowed; all three are
removed endoscopically in 6 months. Intragastric balloon devices used for weight loss are discussed in
detail elsewhere. (See "Bariatric procedures for the management of severe obesity: Descriptions", section
on 'Intragastric balloon'.)

● Gastric emptying (aspiration) systems – A surgically placed gastrostomy tube is used to drain a portion
of the stomach contents after every meal, decreasing the calories absorbed. These are intended to assist in
weight loss in patients aged 22 and older with a BMI of 35 to 55 kg/m2, and who have failed to achieve and
maintain weight loss through nonsurgical weight loss therapy. These devices are contraindicated in
patients with eating disorders. Gastric emptying (aspiration) therapy is reviewed elsewhere. Of note, the
gastric emptying aspiration system (AspireAssist) is no longer available in the United States. (See "Bariatric
procedures for the management of severe obesity: Descriptions", section on 'Aspiration therapy'.)

● Hydrogels – Considered medical devices, hydrogels are orally administered products, taken twice daily
before meals, which expand in the stomach and intestines to create a sensation of satiety. They are not
systemically absorbed and are eliminated through the feces. Hydrogels are indicated for use as weight
management aids for adults with a BMI of 25 to 40 kg/m2 and are to be used in conjunction with diet and
 exercise. There is no restriction on how long the product can be used for weight management. In a
randomized trial comparing patients taking 2.25 g twice daily of a cellulose and citric acid hydrogel product
versus placebo for 24 weeks, those taking the hydrogel lost more weight (6.4 versus 4.4 percent) [37].
Prescribing information for cellulose and citric acid hydrogel is available in the drug monograph included
within UpToDate.

● Bariatric endoscopy – Bariatric endoscopy includes the placement of gastric balloons as well as
endoscopic sleeve gastroplasty (a procedure which uses a suturing device which creates a tubular shape
similar to the sleeve gastrectomy). Further description of these techniques is beyond the scope of this
document.

Bariatric surgery — Candidates for bariatric surgery include adults with a BMI ≥35 kg/m2, or a BMI of 30 to
34.9 kg/m2 with type 2 diabetes [38]. There is some evidence that the BMI criteria may differ among races. (See
"Bariatric surgery for management of obesity: Indications and preoperative preparation".)

Several surgical approaches, collectively referred to as "bariatric surgery," have been used to treat obesity. All
procedures, including investigational ones such as endoscopic sleeve gastroplasty, are reviewed separately.
Bariatric surgical approaches can achieve as much as a 40 percent weight loss at 12 to 18 months post-
procedure, with better long-term weight loss maintenance than nonsurgical approaches. (See "Bariatric
procedures for the management of severe obesity: Descriptions".)

In addition to resulting in greater weight loss, bariatric surgery may also reduce obesity-related morbidity more
than nonsurgical weight loss approaches. In the Swedish Obese Subjects (SOS) after 10 to 20 years of follow-up,
patients receiving bariatric surgery (including gastric banding, vertical banded gastroplasty, gastric bypass) had
greater reductions in obesity-related morbidity (diabetes, hypertension, dyslipidemia) and overall mortality than
those in the conventionally treated group (hazard ratio [HR] 0.71, 95% CI 0.54-0.92) [16]. In a subsequent
propensity score matched cohort study, 2161 patients with type 2 diabetes and severe obesity who underwent
metabolic bariatric surgery were compared with 2161 similar nonsurgical patients treated with GLP-1 receptor
agonists (81.7 percent liraglutide) [39]. During the study period, fewer surgical patients suffered major
cardiovascular adverse events (MACE) or all-cause mortality than nonsurgical patients (8-year cumulative
incidence 9.3 versus 11.3 percent, HR 0.76, 95% CI 0.59-0.98).

Further, in systematic reviews and meta-analyses of randomized trials comparing bariatric surgery with
nonsurgical treatment of obesity (diet, exercise, weight-reducing drugs, behavioral therapy), there was greater
weight loss and higher remission rates of type 2 diabetes in the bariatric surgery group [40,41]. Such results
were further magnified when bariatric surgery was combined with intensive medical therapy [42]. The surgical
management of obesity is reviewed in detail separately. (See "Bariatric surgery for management of obesity:
Indications and preoperative preparation" and "Management of persistent hyperglycemia in type 2 diabetes
mellitus", section on 'Bariatric (metabolic) surgery' and "Outcomes of bariatric surgery".)

THERAPIES THAT WE DO NOT RECOMMEND

Liposuction — We do not advocate liposuction as a strategy for long-term weight loss. Removal of fat by
aspiration after injection of physiologic saline has been used to remove and contour subcutaneous fat. While
this can result in a significant reduction in fat mass and weight, it does not appear to improve insulin sensitivity
or risk factors for coronary heart disease. This was illustrated in a study of 15 obese women (eight with normal
glucose tolerance and seven with type 2 diabetes) who underwent metabolic evaluation before and 10 to 12
weeks after large-volume abdominal liposuction with the following results [43]:
 ● Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent (9 kg) in the
women with normal glucose tolerance and by 28 percent (10.5 kg) in those with diabetes.

● Although waist circumference and plasma leptin concentrations were significantly decreased, no
improvements in insulin sensitivity of muscle, liver, or adipose tissue were seen in either group.

● Liposuction did not alter plasma concentrations of C-reactive protein, interleukin-6, tumor necrosis factor-
alpha, or adiponectin, and there were no significant improvements in other risk factors for coronary heart
disease, including blood pressure, plasma glucose, lipid, or insulin concentrations. (See "Overview of
established risk factors for cardiovascular disease".)

Thus, removal of large volumes of subcutaneous abdominal adipose tissue with liposuction does not improve
insulin sensitivity or risk factors for coronary heart disease in women with obesity with or without type 2
diabetes, suggesting that the negative energy balance induced by decreased nutritional intake and/or removal
of visceral fat are necessary for achieving the metabolic benefits of weight loss. (See "Obesity in adults: Dietary
therapy".)

HCG — There is no evidence that treatment with human chorionic gonadotropin (HCG) is effective in the
treatment of obesity [44]. Well-conducted trials have shown that it does not induce weight loss or fat
redistribution, nor does it reduce hunger.

Dietary supplements — Although over-the-counter dietary supplements are widely used by individuals
attempting to lose weight, we advise against their use because evidence to support their efficacy and safety are
limited. Examples of dietary supplements include ephedra, green tea, chromium, chitosan, Vitamin B-12, and
guar gum. Ephedra and ephedra alkaloids (Ma Huang), a group of ephedrine-like molecules found in plants,
have been removed from the United States market because of safety concerns. (See "Obesity in adults: Drug
therapy", section on 'Therapies not recommended' and "High-risk dietary supplements: Patient evaluation and
counseling", section on 'Weight loss supplements'.)

Acupuncture — Acupuncture has also been studied for the treatment of obesity. While most studies have been
uncontrolled trials, results from some, but not all, controlled trials have shown modest benefit of acupuncture
for weight loss [45,46]. However, the majority of these controlled trials are small, of short duration, and do not
include adequate placebo controls.

RISKS OF TREATMENT

Treatments for obesity can be divided according to the risk of side effects. For example, most of the available
antiobesity drugs have minor side effects that diminish with treatment; however, a few serious side effects have
been identified that should preclude short-term use in people who wish to lose small amounts of weight (the
majority of people) [47,48]. Chronic treatment may be needed when the magnitude of the obesity carries larger
risks (eg, a BMI above 30 kg/m2, or a BMI between 27 and 30 kg/m2 with complicating factors such as diabetes
mellitus or hypertension). (See "Obesity in adults: Drug therapy".)

Significant weight loss (achieved via any modality) may increase the likelihood of cholelithiasis because the flux
of cholesterol through the biliary system increases. Diets with moderate amounts of fat that trigger gallbladder
contraction may reduce this risk. Similarly, therapy with a bile acid (eg, ursodeoxycholic acid) may be advisable
in selected subjects, such as those who are losing weight rapidly (>1 to 1.5 kg/week).
MAINTENANCE OF WEIGHT LOSS

Recidivism, the regaining of lost weight, is a common problem in treating people with obesity [49].

Characteristics of those who are likely to succeed in maintaining weight loss include frequent self-weighing, a
larger initial weight loss (>2 kg in four weeks), frequent and regular attendance at a weight loss program, a
belief that their weight can be controlled, consumption of a reduced calorie (eg, 1400 kcal/day) low-fat diet,
regular physical activity, and participation in a lifestyle intervention program [50,51]. (See "Obesity in adults:
Behavioral therapy", section on 'Maintenance of weight loss' and "Obesity in adults: Dietary therapy", section on
'Role of dietary counseling' and "Obesity in adults: Role of physical activity and exercise", section on 'Exercise
may help maintain weight loss'.)

The body appears to have a "set point" of adipose tissue mass, and after weight loss, counter-regulatory
hormones are secreted to re-establish the higher body weight. In addition, the reduction in energy expenditure
caused by weight loss itself contributes to the difficulty in maintaining weight loss [52-54]. (See "Obesity: Genetic
contribution and pathophysiology", section on 'Resistance to weight loss and maintenance of reduced weight'.)

Lifestyle modification strategies that include diet and exercise remain the foundation of any long-term weight
management plan. However, strategies that assume the effective treatment of obesity is only a matter of an
individual's "willpower" may lead to repeated failure due to the body's tendency to revert to its set point [52].
Bariatric surgery, which may alter the body's adipose tissue set point, and extended use of antiobesity
pharmacologic therapy may help address these underlying physiologic changes. (See "Outcomes of bariatric
surgery" and "Obesity in adults: Drug therapy".)

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions around the world
are provided separately. (See "Society guideline links: Obesity in adults".)

INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics
patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the
four or five key questions a patient might have about a given condition. These articles are best for patients who
want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education
pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade
reading level and are best for patients who want in-depth information and are comfortable with some medical
jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these
topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on
"patient info" and the keyword(s) of interest.)

● Basics topics (see "Patient education: Weight loss treatments (The Basics)")

● Beyond the Basics topics (see "Patient education: Losing weight (Beyond the Basics)")
SUMMARY AND RECOMMENDATIONS

● Benefits of weight loss – The medical rationale for weight loss is that obesity is a serious, chronic, and
progressive disease and is associated with a significant increase in mortality ( figure 1) and many health
risks including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. The
benefits of weight loss include a reduction in the rate of progression from impaired glucose tolerance to
diabetes, blood pressure in hypertensive patients, and lipid levels in higher risk patients. Other noncardiac
benefits of weight loss include reductions in urinary incontinence, sleep apnea, and depression, as well as
improvements in quality of life, physical functioning, and mobility. (See 'Importance of weight loss' above.)

● Identify candidates for treatment – Selection of treatment for people with overweight or obesity is
based upon an initial risk assessment. (See 'Identify candidates' above.)

● Lifestyle modifications for all individuals – All patients who would benefit from weight loss should
receive counseling on diet, exercise, and goals for weight management. (See 'Initial treatment' above.)

● Pharmacologic therapy – Candidates for pharmacologic therapy include adults with a body mass index
(BMI) greater than 30 kg/m2, or a BMI of 27 to 29.9 kg/m2 with comorbidities, who have not met weight
loss goals (loss of at least 5 percent of total body weight at three to six months) with a comprehensive
lifestyle intervention. The decision to initiate drug therapy should be individualized and made after a
careful evaluation of the risks and benefits of all treatment options (lifestyle, pharmacologic, surgical).
Detailed recommendations for pharmacotherapy are discussed separately. (See 'Drug therapy' above and
"Obesity in adults: Drug therapy".)

● Devices for weight loss – There are several types of devices approved for use in the treatment of obesity.
The use of one of these devices may be considered for use in those patients in whom medications are
ineffective or not tolerated, for those patients who are unable or unwilling to undergo bariatric surgery, or
as a bridging therapy prior to bariatric surgery. In referring a patient to receive one of these devices, it is
important to note that the BMI indication for each device is different, with a BMI range between 25 to 55
kg/m2. (See 'Devices' above.)

● Bariatric surgery – Candidates for bariatric surgery include adults with a BMI ≥35 kg/m2, or a BMI of 30 to
34.9 kg/m2 with type 2 diabetes mellitus. (See 'Bariatric surgery' above.)

● Strategies to maintain weight loss – Consumption of a reduced calorie diet, frequent self-weighing, and
participation in a lifestyle intervention program are strategies to help maintain weight loss. However, the
body appears to have a "set point" of adipose tissue mass, and strategies that assume the effective
treatment of obesity is only a matter of an individual's "willpower" may lead to repeated failure due to the
body's tendency to revert to its set point. Bariatric surgery, which may alter the body's adipose tissue set
point, and extended use of antiobesity pharmacologic therapy may help address these underlying
physiologic changes. (See 'Maintenance of weight loss' above.)

ACKNOWLEDGMENT

The UpToDate editorial staff acknowledges George Bray, MD, who contributed to an earlier version of this topic
review.

Use of UpToDate is subject to the Terms of Use.

REFERENCES

1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight
and obesity in adults: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129:S102.

2. Centers for Disease Control and Prevention. Overweight & obesity. Available at: https://www.cdc.gov/obesit
y/index.html (Accessed on March 06, 2020).

3. Look AHEAD Research Group, Gregg EW, Jakicic JM, et al. Association of the magnitude of weight loss and
changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people
with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes
Endocrinol 2016; 4:913.

4. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical

treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre,
randomised controlled trial. Lancet 2015; 386:964.

5. Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients With
Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady
Hypertension). Circulation 2018; 137:1132.

6. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle
intervention or metformin. N Engl J Med 2002; 346:393.

7. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes
incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677.

8. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on
diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention
Program Outcomes Study. Lancet Diabetes Endocrinol 2015; 3:866.

9. Lee CG, Heckman-Stoddard B, Dabelea D, et al. Effect of Metformin and Lifestyle Interventions on Mortality
in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care
2021; 44:2775.
10. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission
of type 2 diabetes. JAMA 2012; 308:2489.
11. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes
(DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391:541.
12. Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive
patients: systematic review and meta-analysis. Arch Intern Med 2008; 168:571.
13. Poobalan AS, Aucott LS, Smith WC, et al. Long-term weight loss effects on all cause mortality in
overweight/obese populations. Obes Rev 2007; 8:503.

14. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in
obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005; 29:1153.

15. Fisher DP, Johnson E, Haneuse S, et al. Association Between Bariatric Surgery and Macrovascular Disease
Outcomes in Patients With Type 2 Diabetes and Severe Obesity. JAMA 2018; 320:1570.
16. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled
intervention study of bariatric surgery. J Intern Med 2013; 273:219.
17. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;
357:753.
18. Sjöström L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J
Obes (Lond) 2008; 32 Suppl 7:S93.

19. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival.
JAMA 2015; 313:62.

20. Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis
of randomized clinical trials. PLoS One 2015; 10:e0121993.

21. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular
disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes
Care 2007; 30:1374.

22. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle
intervention in type 2 diabetes. N Engl J Med 2013; 369:145.

23. Arterburn DE, O'Connor PJ. A look ahead at the future of diabetes prevention and treatment. JAMA 2012;
308:2517.

24. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet 2016; 387:1947.

25. Vallis M. Quality of life and psychological well-being in obesity management: improving the odds of success
by managing distress. Int J Clin Pract 2016; 70:196.

26. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or
Obesity. N Engl J Med 2021; 384:989.

27. US Preventive Services Task Force, Curry SJ, Krist AH, et al. Behavioral Weight Loss Interventions to Prevent
Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation
Statement. JAMA 2018; 320:1163.

28. Bray GA, Kim KK, Wilding JPH, World Obesity Federation. Obesity: a chronic relapsing progressive disease
process. A position statement of the World Obesity Federation. Obes Rev 2017; 18:715.

29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description
of lifestyle intervention. Diabetes Care 2002; 25:2165.

30. Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary care-relevant treatments for obesity in
adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;
155:434.
31. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight
and obesity in adults: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014; 63:2985.

32. Perri MG, Nezu AM, McKelvey WF, et al. Relapse prevention training and problem-solving therapy in the
long-term management of obesity. J Consult Clin Psychol 2001; 69:722.

33. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone
diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293:43.

34. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver
Spring) 2006; 14:1283.

35. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older
Adults. N Engl J Med 2017; 376:1943.

36. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA 2018; 320:2020.
37. Greenway FL, Aronne LJ, Raben A, et al. A Randomized, Double-Blind, Placebo-Controlled Study of
Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity (Silver Spring) 2019; 27:205.
 38. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS)
and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for
Metabolic and Bariatric Surgery. Surg Obes Relat Dis 2022; 18:1345.
39. Stenberg E, Näslund E. Major adverse cardiovascular events among patients with type-2 diabetes, a
nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist
treatment. Int J Obes (Lond) 2023; 47:251.

40. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic
review and meta-analysis of randomised controlled trials. BMJ 2013; 347:f5934.
41. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst
Rev 2014; :CD003641.
42. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-
Year Outcomes. N Engl J Med 2017; 376:641.
43. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for
coronary heart disease. N Engl J Med 2004; 350:2549.
44. Lijesen GK, Theeuwen I, Assendelft WJ, Van Der Wal G. The effect of human chorionic gonadotropin (HCG) in
the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin
Pharmacol 1995; 40:237.

45. Lacey JM, Tershakovec AM, Foster GD. Acupuncture for the treatment of obesity: a review of the evidence.
Int J Obes Relat Metab Disord 2003; 27:419.

46. Hsu CH, Hwang KC, Chao CL, et al. Effects of electroacupuncture in reducing weight and waist
circumference in obese women: a randomized crossover trial. Int J Obes (Lond) 2005; 29:1379.

47. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight
Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016; 315:2424.

48. Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes
Endocrinol 2018; 6:237.

49. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Availabl
e at: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf (Accessed on January 24, 2013).

50. Soini S, Mustajoki P, Eriksson JG. Weight loss methods and changes in eating habits among successful
weight losers. Ann Med 2016; 48:76.

51. Thomas JG, Bond DS, Phelan S, et al. Weight-loss maintenance for 10 years in the National Weight Control
Registry. Am J Prev Med 2014; 46:17.

52. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight
loss. N Engl J Med 2011; 365:1597.

53. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N
Engl J Med 1995; 332:621.

54. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser"
competition. Obesity (Silver Spring) 2016; 24:1612.
Topic 5371 Version 50.0
GRAPHICS

All-cause mortality versus BMI for each sex in the range 15 to 50 kg/m 2 (excluding the first 5
years of follow-up)

Relative risks at age 35 to 89 years, adjusted for age at risk, smoking, and study, were multiplied by a common factor (ie,
floated) to make the weighted average match the PSC mortality rate at ages 35 to 79 years. Floated mortality rates shown
above each square and numbers of deaths below. Area of square is inversely proportional to the variance of the log risk.
Boundaries of BMI groups are indicated by tick marks. 95% CIs for floated rates reflect uncertainty in the log risk for each
single rate. Dotted vertical line indicates 25 kg/m 2 (boundary between upper and lower BMI ranges in this report). Above
25 kg/m 2 , mortality was, on average, approximately 30 percent higher for every 5 kg/m 2 higher BMI.

BMI: body mass index; PSC: Prospective Studies Collaboration.

Reproduced with permission from: Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900,000 adults:
collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083. Illustration used with the permission of Elsevier Inc. All rights reserved.

Graphic 73156 Version 6.0

Waist circumference measurement

Measuring-tape position for waist (abdominal) circumference in adults. To measure waist circumference, locate the upper
hip bone and the top of the right iliac crest. Place a measuring tape in a horizontal plane around the abdomen at the level
of the iliac crest. Before reading the tape measure, ensure that the tape is snug, but does not compress the skin, and is
parallel to the floor. The measurement is made at the end of a normal expiration.

Reproduced from: National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in
Adults. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart Lung and Blood Institute,
Bethesda, MD, October 2000.

Graphic 77584 Version 1.0

Intragastric balloon

The intragastric balloon is a temporary alternative for weight loss in individuals with moderate obesity. It consists of a soft,
saline-filled balloon placed endoscopically that promotes a feeling of satiety and restriction.

Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury,
Connecticut 2010. Copyright © 2010 Cine-Med.

Graphic 58305 Version 3.0

Contributor Disclosures
Leigh Perreault, MD Consultant/Advisory Boards: Eli Lilly [Obesity]; Novo Nordisk [Obesity]. Speaker's Bureau: Eli Lilly
[Obesity]; Novo Nordisk [Obesity]. All of the relevant financial relationships listed have been mitigated. Caroline Apovian,
MD Grant/Research/Clinical Trial Support: GI Dynamics Inc [Obesity/weight management]; NIH [Metabolism/Obesity]; PCORI
[Obesity/weight management]. Consultant/Advisory Boards: Altimmune [Obesity/weight management]; Cowen and
Company [Obesity/weight management]; Currax Pharmaceuticals, LLC [Obesity/weight management]; EPG Communication
Holdings Ltd [Obesity/weight management]; Form Health, Inc. [Obesity/weight management]; Gelesis, Srl. [Obesity/weight
management]; L-Nutra, Inc. [Obesity/weight management]; NeuroBio [Obesity/weight management]; Novo Nordisk
[Obesity/weight management]; Pain Script Corporation [Obesity/weight management]; Pursuit By You [Obesity/weight
management]; ReShape Lifesciences Inc. [Obesity/weight management]; Riverview School [Obesity/weight management];
Xeno Biosciences [Obesity/weight management]. All of the relevant financial relationships listed have been mitigated. F
Xavier Pi-Sunyer, MD, MPH No relevant financial relationship(s) with ineligible companies to disclose. David Seres,
MD Equity Ownership/Stock Options: Biomed Industries, Inc. [Biomedical informatics, drug development (Alzheimer’s and
obesity)]. Grant/Research/Clinical Trial Support: Nasotrak Medical Pte, Ltd [Feeding tube technology, safety study].
Consultant/Advisory Boards: Community Surgical Supply [Outpatient infusion pharmacy and DME, parenteral nutrition]. All
of the relevant financial relationships listed have been mitigated. Sara Swenson, MD No relevant financial relationship(s)
with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by
vetting through a multi-level review process, and through requirements for references to be provided to support the
content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy